A new Mayo Clinic study found the prostate-specific antigen test was accurate in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a news release said.
More than 600 men between the ages of 40 and 79 were prospectively followed since 1990. The study found men in their 40s and 50s with a baseline PSA at or above the median were much more likely to both undergo a biopsy and be diagnosed with low-risk prostate cancer.
Related Articles about Prostate Cancer:
Physicians Question Federal Panel's Recommendation on Prostate Screening Tests
Vitamin E Linked to Higher Risk of Prostate Cancer
Tool Determines Risk of Death of Prostate Cancer Patients After Radiation
More than 600 men between the ages of 40 and 79 were prospectively followed since 1990. The study found men in their 40s and 50s with a baseline PSA at or above the median were much more likely to both undergo a biopsy and be diagnosed with low-risk prostate cancer.
Related Articles about Prostate Cancer:
Physicians Question Federal Panel's Recommendation on Prostate Screening Tests
Vitamin E Linked to Higher Risk of Prostate Cancer
Tool Determines Risk of Death of Prostate Cancer Patients After Radiation